Standard Contracts
CHIRON CORPORATION AMENDED AND RESTATED BYLAWS INDEXBylaws • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations
CHIRON LETTERHEAD]Employment Agreement • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations
John A. Lambert Vice President; President, Chiron Vaccines Chiron Vaccines, Florey House Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA England, United Kingdom
AMENDMENT NO. 5 TO AGREEMENTAgreement • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations
This Amendment No. 5 ("Amendment No. 5") is entered into effective as of January 1, 2004 (the "Amendment Effective Date"), pursuant to and amending that certain Agreement between Gen-Probe Incorporated, a Delaware corporation ("Gen-Probe") and Chiron Corporation, a Delaware corporation ("Chiron"). Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.
NOVARTIS AG WRITTEN CONSENT AND APPROVAL Effective as of December 5, 2003Stock Repurchase Plan • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations
WHEREAS, Section 2.04 (a)(iii) of that certain Governance Agreement dated as of November 20, 1994 between Chiron Corporation ("Chiron" or the "Company") and Novartis AG (the "Governance Agreement"), requires the consent of Novartis AG in connection with any reclassification, combination, split, subdivision, or redemption, purchase or other acquisition, directly or indirectly, of any debt or equity securities or other capital stock of the Company;
FUTURE BLOOD SCREENING ASSAY— ULTRIO ADDENDUM AMENDING AGREEMENT ENTERED INTO AS OF JUNE 11, 1998 BY AND BETWEEN GEN-PROBE INCORPORATED, A DELAWARE CORPORATION AND CHIRON CORPORATIONFuture Blood Screening Assay—ultrio Addendum • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations
This Future Blood Screening Assay—Ultrio Addendum (the "Ultrio Addendum") is entered into, effective as of January 1, 2001 (the "Addendum Effective Date") pursuant to and amending that certain Agreement entered into as of June 11, 1998 (the "Agreement") by and between Gen-Probe Incorporated, a Delaware corporation ("Gen-Probe") with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Chiron Corporation, a Delaware corporation ("Chiron;" collectively with Gen-Probe, the "parties") with a place of business at 4560 Horton Street, Emeryville, CA 94608.
INTERCITY PHARMA LIMITED (1) and EVANS VACCINES LIMITED (2) AGREEMENT FOR LEASE relating to Unit 5A Boulevard Industry Park Halewood MerseysideAgreement for Lease • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations • England
INTERCITY PHARMA LIMITED (Company Number 4703226) whose registered office is at The Customs House 7 Union Street Liverpool L3 9QX ("Developer")
CONFIDENTIAL TREATMENT REQUESTED*** FUTURE BLOOD SCREENING ASSAY— WEST NILE VIRUS ADDENDUM AMENDING AGREEMENT ENTERED INTO AS OF JUNE 11, 1998 BY AND BETWEEN GEN-PROBE INCORPORATED, A DELAWARE CORPORATION AND CHIRON CORPORATIONFuture Blood Screening Assay—west Nile Virus Addendum • March 3rd, 2004 • Chiron Corp • Pharmaceutical preparations
This Future Blood Screening Assay—West Nile Virus Addendum (the "West Nile Virus Addendum") is entered into, effective as of June 1, 2003 (the "Addendum Effective Date") pursuant to and amending that certain Agreement entered into as of June 11, 1998 (the "Agreement") by and between Gen-Probe Incorporated, a Delaware corporation ("Gen-Probe") with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Chiron Corporation, a Delaware corporation ("Chiron;" collectively with Gen-Probe, the "parties") with a place of business at 4560 Horton Street, Emeryville, CA 94608.
